Dr. Einav Gal-Yam, MD, PhD
- Breast cancer
My activities are supported by the Talpiot Medical Leadership Program of the Chaim Sheba Medical Center, the Israeli Science Foundation (Heritage Legacy Fund), the Ministry of Health – fund for physician investigator, the Weizmann –Sheba Grant, the EU via the FP7 – Marie Curie – International Reintegration Grant (IRG) and the Israel Cancer Association .
Research: Cancer Epigenetics
Oncology Department, Laboratory of cancer epigenetics, Sheba Medical Center, Tel-Hashomer
- Head of Breast Oncology Institute
- 2007: present Resident, Oncology Department, Sheba Medical Center, Tel-Hashomer, affiliated to the Tel-Aviv University, Israel.
- Fellow, the Talpiot Excellence and Medical Leadership Program
- Head- laboratory of cancer epigenetics, Sheba Medical Cancer Center
- 2004 - 2007: Post Doctoral scholar at the Norris Cancer Center, University of Southern California, Los-Angeles, CA, USA.
- 2002 - 2003 Medical Intern, Souraski Medical Center, Tel-Aviv, Israel
- 2002 Research Assistant – Hemato-Onclogy lab, Sheba Medical Center , Tel-Hashomer , affiliated to the Tel-Aviv University, Israel.
Education and Training
- 1996 - 2003: MD – Ph.D. (member of the MD-Ph.D program), Sackler School of medicine, Tel-Aviv University, Israel.
- Ph.D. - Human Genetics, Sackler School of medicine, Tel-Aviv University, Israel. Advisor: Prof. Gidi Rechavi.
- M.D. - Sackler School of medicine, Tel-Aviv University, Israel. 1993 – 1996 B.Med.Sc. Magna Cum Laude in Medical Sciences, Tel-Aviv University.
Tamar Rubinek1, Michal Shulman1, Shira Israeli1,Bose Shikha3,Ayelet Avraham4, Adi Zundelevich, Ella Evron4, Einav Nili- Gal-Yam1, Bella Kaufman1, Ido Wolf Epigenetic silencing of the tumor suppressor kloth an early event in breast cancer development . In preparation.
Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2010 Aug 6.
Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, Jones PA and Tanay A (2008) Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line, Proc Nat Acad Sci USA 105: 12979-984
van Rietschoten JG, Gal-Yam EN, Jeong S, Cortez CC, Verweij CL, Jones PA. (2008). Epigenetic regulation and nucleosome positioning in the human TATA-less IL-1alpha promoter. Genes Immun. 9(7):582-90
Shakali S, Somech R, Geller O, Avigad Y, Gal-Yam EN, Hirschberg K, Amariglio N, Simon AJ, Rechavi G (2008). Lap2 translocates BAF to the cytoplasm disrupting nuclear envelope mediated transcriptional repression. Eur J Cell Biol. ;87(5):267-78
Gal-Yam EN, Saito Y, Egger G and Jones PA (2008). Cancer Epigenetics: Modifications, Screening, and Therapy. Annu. Rev. Med. 59: 491-504
Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, Egger G, Gal-Yam EN and Jones PA (2007). Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG Island. Cancer Cell 12(5):432-441
Somech R, Gal-Yam EN, Shaklai S, Geller O, Amariglio N, Rechavi G and Simon AJ (2007). Enhanced expression of the nuclear envelope LAP2 transcriptional repressors in normal and malignant activated lymphocytes. Ann Hematol 86(6):393-401.
Gal-Yam EN, Jeong S, Tanay A, Egger G, Lee AS, Jones PA. (2006). Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genetics 22;2(9):e160.
Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, Jones PA. (2005). Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 33(20):e176.
Somech R, Shaklai S, Simon AJ, Amariglio N, Rechavi G, Nili Gal-Yam E. (2005). The nuclear-envelope protein and transcriptional repressor LAP2beta interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation. J Cell Sci 18:4017-4025.
Kleiman S., Yogev L., Nili Gal-Yam E, Hauser R, Gamzu R, Botchan A, Paz G, Yavetz H,Bar-Shira Maymon B, Schreiber L, Barzilai S, Amariglio N, Rechavi G, Simon AJ. (2003). Reduced germ cell less (HGCL) expression in azoospermic men with severe germinal cell impairment. J. Androl 24:670-675
Nili E, Cojocaru GS, Kalma Y, Ginsberg D, Copeland NG, Gilbert DJ, Jenkins NA, Berger R, Shaklai S, Amariglio N, Brok-Simoni F, Simon AJ, Rechavi G. (2001) Nuclear membrane protein LAP2beta mediates transcriptional repression alone and together with its binding partner GCL (germ-cell-less).J. Cell Sci 114:3297-3307
Nili, E., Cojocaru, G. S., Collin, G. B., Nishina, P. M., Brok-Simoni, F., Amariglio, N., Simon, A. J. and Rechavi, G. (2001). The human germ-cell-less (HGCL): a candidate gene for Alstrom Syndrome. J. Endocrinol. Genet. 2: 29-35.
Goldberg M, Nili E, Cojocaru G, B.Tzur Y, Berger R, Brandies M, Rechavi G, Gruenbaum Y, Simon AJ. (1999). Functional Organization of the Nuclear Lamina. Gene Therapy and Molecular Biology. 4: 143-158
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: